M&A NEWS

Lilly agrees up-to-US$1.5bn deal for Calytrix Bio

The drugmaker adds an early-stage antibody for mutant calreticulin-driven myeloproliferative neoplasms to its blood cancer pipeline.

M&A News deals deskHealthcare / Biotech · United States, Americas16 Nov 2026

Calytrix Bio said on 16 November 2026 it had agreed to be acquired by Eli Lilly for up to US$1.5bn in cash, including an upfront payment and later milestone payments.

Why Eli Lilly and Company is buying Calytrix Bio, Inc.

Calytrix's lead candidate is a biparatopic antibody designed to target mutant calreticulin, a driver of essential thrombocythemia and myelofibrosis. Chief executive Brad Prosek said the company was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms.

Deal terms and financing

Payments depend on clinical and regulatory milestones; the upfront amount and expected closing date were not disclosed.

Market context

Calytrix was launched in 2025 out of J.P. Morgan Life Sciences Private Capital and later raised a Series B with Avoro Ventures. BioSpace counted it as Lilly's 14th disclosed acquisition of 2026, following its purchase of Ajax Therapeutics, another myelofibrosis developer.

More United States M&A news

All United States deals →